Get the Stockscreener App
5.94
4.95%
0.28
After Hours:
5.93
-0.01
-0.17%
Solid Biosciences Inc stock is traded at $5.94, with a volume of 141.80K.
It is up +4.95% in the last 24 hours and down -9.73% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$5.66
Open:
$5.63
24h Volume:
141.80K
Relative Volume:
0.54
Market Cap:
$229.26M
Revenue:
$14.79M
Net Income/Loss:
$-96.02M
P/E Ratio:
-0.9617
EPS:
-6.1766
Net Cash Flow:
$-95.70M
1W Performance:
+4.39%
1M Performance:
-9.73%
6M Performance:
-41.19%
1Y Performance:
+109.15%
1-Day Range:
$5.61
$5.94
1-Week Range:
$5.46
$5.99
52-Week Range:
$2.00
$15.05
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - PR Newswire UK
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Millennium Management LLC Reduces Stake in Solid Biosciences Inc - GuruFocus.com
Sow Good to Hold Third Quarter 2024 Conference Call on Thursday, November 14, 2024 at 10:00 a.m. ET - The Manila Times
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium - GlobeNewswire
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire
Duchenne Muscular Dystrophy Therapeutics Market Trends, Growth Insights, and Forecasts 2033 - WhaTech
WRN inhibitor IDE-275 gains IND clearance for phase I study in MSI-high tumors - BioWorld Online
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - BioSpace
(SLDB) Proactive Strategies - Stock Traders Daily
Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal™ CDx Pan-Cancer Solid tumor IVD Kit - PR Newswire
Solid Biosciences CMO sells $18,999 in stock - Investing.com India
Solid Biosciences CMO sells $18,999 in stock By Investing.com - Investing.com Canada
Insider Selling: Solid Biosciences Inc. (NASDAQ:SLDB) Insider Sells 2,923 Shares of Stock - MarketBeat
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - Quantisnow
Seraxis gains IND clearance for islet replacement therapy - BioWorld Online
(SLDB) Trading Signals - Stock Traders Daily
Solid Biosciences Inc (SLDB) did well last session? - US Post News
Keeping an Eye on Solid Biosciences Inc (SLDB) After Insider Trading Activity - Knox Daily
Cubist Systematic Strategies LLC Sells 74,908 Shares of Huron Consulting Group Inc. (NASDAQ:HURN) - Defense World
Cubist Systematic Strategies LLC Has $368,000 Stock Position in Metropolitan Bank Holding Corp. (NYSE:MCB) - Defense World
Cubist Systematic Strategies LLC Makes New $378,000 Investment in Cryoport, Inc. (NASDAQ:CYRX) - Defense World
Great Lakes Dredge & Dock Co. (NASDAQ:GLDD) Shares Sold by Cubist Systematic Strategies LLC - Defense World
Cubist Systematic Strategies LLC Makes New $362,000 Investment in Anterix Inc. (NASDAQ:ATEX) - Defense World
Aegon Ltd. (NYSE:AEG) Stake Raised by Cubist Systematic Strategies LLC - Defense World
SG Americas Securities LLC Lowers Stock Position in Pool Co. (NASDAQ:POOL) - Defense World
Lindsay Co. (NYSE:LNN) Shares Sold by Cubist Systematic Strategies LLC - Defense World
Cubist Systematic Strategies LLC Sells 23,029 Shares of The St. Joe Company (NYSE:JOE) - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Ono and Ligachem sign licensing agreement for ADC LCB-97 for solid tumors - BioWorld Online
SLDB (Solid Biosciences Inc) may reap gains as insiders became active recently - Knox Daily
Nona Biosciences Enters Strategic Collaboration with OverT Bio to Advance Next-Generation Cell Therapies for Solid Tumors - BioSpace
A Deep Dive into Solid Biosciences Inc (SLDB) Stock Performance - The InvestChronicle
Solid Biosciences Inc. (NASDAQ:SLDB) Shares Acquired by Millennium Management LLC - MarketBeat
MBX Biosciences outlook solid with JPMorgan's overweight rating, eyes key catalysts in next 12 months - Investing.com
Marshall Wace LLP Invests $1.55 Million in Solid Biosciences Inc. (NASDAQ:SLDB) - MarketBeat
Renaissance Technologies LLC Acquires 208,793 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - MarketBeat
(SLDB) Investment Analysis - Stock Traders Daily
Fresh Study Reveals the Duchenne Muscular Dystrophy Market Insights, Demand, and Forecast to 2033 - WhaTech
Solid Biosciences' SWOT analysis: DMD therapy stock faces pivotal data - Investing.com
Deerfield Management Company L.P. Series C Lowers Position in Solid Biosciences Inc. (NASDAQ:SLDB) - MarketBeat
Duchenne Muscular Dystrophy Treatment Drugs, Clinical Trials, Pipeline Insights and Companies 2024 - The Globe and Mail
Is Solid Power, Inc. (SLDP) the Most Promising EV Battery Stock According to Analysts? - Insider Monkey
The Trailer for Ryan Coogler’s Horror Film Sinners Is Appealingly Mysterious - Reactor
Sinners: Ryan Coogler’s Latest Gets a Thrilling First Trailer - Cinelinx
Solid Power, Inc. (NASDAQ:SLDP) Stock Position Reduced by Sagefield Capital LP - Defense World
Inspire Investing LLC Boosts Stake in Silicon Laboratories Inc. (NASDAQ:SLAB) - Defense World
The First Trailer For Ryan Coogler's Sinners Drops Tomorrow - Bleeding Cool News
Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference - GlobeNewswire
Lysosomal Disease Treatment Market Size, Analysis, Trends, Opportunities 2024-2033 - WhaTech
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Solid Biosciences Inc Stock (SLDB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kahn Clare | Director |
Jun 07 '24 |
Buy |
7.67 |
1,100 |
8,442 |
1,100 |
| Ganot Ilan | Director |
May 02 '24 |
Sale |
10.33 |
462 |
4,772 |
9,507 |
| Ganot Ilan | Director |
Jan 29 '24 |
Sale |
7.99 |
139 |
1,111 |
8,416 |
| PERCEPTIVE ADVISORS LLC | Director |
Jan 11 '24 |
Buy |
5.53 |
3,410,713 |
18,861,243 |
6,833,539 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jan 11 '24 |
Buy |
5.53 |
904,160 |
5,000,005 |
4,192,216 |
| Tan Kevin | CFO & Treasurer |
Jan 09 '24 |
Sale |
8.20 |
3,935 |
32,267 |
9,308 |
| Ganot Ilan | Director |
Jan 03 '24 |
Sale |
5.30 |
1,142 |
6,052 |
8,167 |
| Cumbo Alexander | President and CEO |
Dec 04 '23 |
Sale |
2.77 |
11,757 |
32,516 |
17,439 |
| Howton David T | Chief Operating Officer |
Dec 04 '23 |
Sale |
2.78 |
5,367 |
14,920 |
7,684 |
| Herzich Paul | Chief Technology Officer |
Dec 04 '23 |
Sale |
2.77 |
2,968 |
8,232 |
4,270 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):